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Abstract: 
We design a “simple” and “low cost” model technology for monitoring HIV patients CD4 number in resource-poor settings: 
SMARThivCD4mos. Cost and complexity are the major challenges to the developing world in transferring and implementing HIV 
surveillance technologies. We previously proposed a “three tests” combo kit model for improving HIV patients monitoring 
standards in resource-poor settings. From the pool of recommended alternative CD4 counting technologies, our “three tests” combo 
kit model retained the Capcellia technology for its “simplicity”. However, compared to other CD4 counting technologies, such as 
Dynabeads, the Capcellia technology is “expensive”. Here, we describe a cost reduction strategy of the Capcellia technology.  
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Background: 
CD4 number is a marker used in the clinical management of 
HIV patients to make important decisions including 
classifying diseases stages, monitoring disease progression, 
and guiding initiation of AntiRetroViral (ARV) treatment.  
CD8 cells are a subset of immune cells different from CD4 
that are used as marker in monitoring other immune disorders, 
but not recommended in the World Health Organisation 
guidelines for the clinical management of HIV patients. [1, 2] 
 
Flow cytometry is the standard technology for CD4 counting. 
However, the technology is complex and expensive, and 
requires a high level expertise for implementation, thereby 
limiting its widespread use in resource-poor settings. [1, 2]  
Resources and expertise are scarce in the developing world. 
[1, 2, 3]   
 
Expert panels recommended cheaper and simpler so called 
alternative technologies, for the clinical management of HIV 
patients in the developing world. A number of simpler and 
cheaper CD4 counting technologies amenable to resource-
poor setting, have been developed. [1, 2, 3]   
 
The CD4 counting Dynabeads technology showed a promise 
as an alternative to the standard flow cytometry because of its 
good correlation with the standard flow cytometry. However, 
the technology is complex. The International Medical Center 
of Japan developed a strategy to reduce the complexity and 
the cost of the Dynabeads technology, thereby permitting its 
widespread use in resource-limited situations. [1]   
 
In our SMARThivPack model, we have previously 
demonstrated that cost and complexity of HIV surveillance 
technologies may be reduced, not only at a first technology 
development level, but also at a second technology 
implementation, and a third global coordination levels. Also, 
our SMARThivPack model favours “automation” over 
“manual” text execution, and “three tests” over a “single test” 
in the clinical management of HIV patients in resource-poor 
settings. [3]   
 
The Capcellia technology is an elisa-based CD4 counting 
system. CD4 counting is performed by the “automated” elisa 
plate reader. Our SMARThivPack model determined the 
Capcellia technology as “simple”. However, the Capcellia 
technology is “expensive”. [2, 3]  compared to the $ 3/test 
using the International Medical Center of Japan “Modified 
Dynabeads” protocol, CD4 counting using the Capcellia 
technology is more than 5 times at $ 17/test. [1, 3]   
 
We hypothesize that, by applying the strategy developed at 
the International Medical Center of Japan to reduce cost of the 
“complex” Dynabeads technology, the cost of the “simple” 
but “expensive” Capcellia technology may be reduced, 
thereby combining “simplicity” with “low cost” within a 
“single technology body”: SMARThivCD4mos.  
 
Description: 
We used web-based data mining and detailed investigation of 
existing CD4 counting protocols, to design a model 
technology for monitoring CD4 number in resource-poor 
settings. Using our cost and complexity level standards for 
guidance, we aim to design a CD4 counting system that is 
compatible with our SMARThivPack model. [3]   Our cost 
standard favours “low cost” over “high cost”, and our 
complexity level standard favours “user friendly” 
“automated” text execution, over “manual” test execution. 
Also, our SMARThivPack model favours specialisation to a 
limited number of technologies, over technology and skill 
diversity. In modelling our SMARThivCD4mos we 
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Center of Japan cost reduction strategy of the complex CD4 
Dynabeads technology, to the simple but expensive Capcellia 
technology, could yield a new technology that is both simple 
and cheap (Figure 1), and compatible with our 
SMARThivPack Model. We modelled a first technology 
development level and a second technology implementation 
cost reductions strategies. 
 
 
Figure 1: Comparison of cost and complexity factors (a) of SMARThivCD4mos with the Modified Dynabeads and the Capcellia 
technologies. Lack of resources and expertise are barriers to transfer of expensive and complex technologies to the developing 
world. (b) Cheap and simple technologies are the standards for the developing world (c) The modified Dynabeads technology is 
cheap but complex (d) while the Capcellia technology is simple but expensive (f) SMARThivCD4mos is both cheap and simple.  
 
At the first technology development level, we eliminate the 
CD8 component of the Capcellia kit. Relying on the World 
Health Organisation (WHO) guidelines recommending CD4 
and not CD8 counting in the clinical management of HIV 
patients, the imjc eliminated CD8 counting components of the 
original Dynabeads protocol [1]. We  applied the same 
principle to eliminate the CD8 component of the Capcellia kit. 
However, while the imcj reduced cost of the Dynabeads 
technology at the second implementation level through test 
execution protocol modification, our model reduces cost of 
the Capcellia technology at a first technology development 
level by eliminating CD8 counting components of the 
Capcellia kit. In the original Dynabeads protocol CD8 
counting is a “binding” step. Execution of the original 
protocol commits to counting CD4 cells AND CD8 cells. In 
the Capcellia technology, CD8 counting is optional. The 
Capcellia protocol is constructed with flexibility permitting 
text execution design for counting only “CD4” cells”, OR 
counting only “CD8 cells”. However, the Capcellia kit 
comports both essential components for CD4 and CD8 
counting. The Capcellia kit may be used not only in the 
clinical management of HIV patients, but also in monitoring 
other immune disorders; e.g. after an organ transplant. [2] Our 
SMARThivPack model is designed only for the clinical 
management of HIV patients. Because, the World Health 
Organisation guidelines recommended CD4 counting and not 
CD8 counting in the clinical management of HIV patients, the 
CD8 counting components of the Capcellia kits are therefore 
not essential in the clinical management of HIV patients. 
Therefore, the CD8 counting components are unnecessary 
raising the cost of the Capcellia kit. To reduce cost, our 
SMARThiv CD4mos model eliminates the CD8 counting 
component of the Capcellia kit at the first technology 
development level.  
 
At a second technology implementation level, we modelled a 
cost reduction strategy of the Capcellia technology that 
modified the Capcellia test execution protocol. Both the 
Dynabeads and the Capcellia test execution protocols comport 
a sample preparation step involving T-cells separation from 
whole blood, using magnetic beads. [1, 2] The International 
Medical Center of Japan “Modified Dynabeads” protocol 
reduced cost of the Dynabeads technology by reducing the 
quantity of required beads for T-cell separation. Our 
SMARThivCD4mos model hypothesizes that the cost of the 
Capcellia technology may be similarly reduced by reducing 
the quantity of required beads for T-cell separation. Detailed 
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Dynabeads” protocol is in progress at Biotech tropicana, Inc 
to isolate additional modifiable targets for cost reduction of 
the “simple” but “expensive” Capcellia technology.  
 
SMARThivCD4mos is compatible with our SMARThivPack 
“three tests” combo kit model. Compared to the original 
Dynabeads protocol, the International Medical Center of 
Japan modified protocol is both cheaper and simpler. [1] 
However, our SMARThivPack model previously determined 
the Dynabeads technology as complex. [3] The International 
Medical Center of Japan complexity reduction of the 
Dynabeads technology does not still overcome our 
complexity level standard. The Dynabeads technology relied 
on “manual counting” of CD4 cells. Furthermore, the use of 
microscope required a different skill from the skills required 
in elisa assays preferred in our SMARThivPack model. Based 
on the complexity level standard in our SMARThivPack 
model, “automation” should always be favoured over “manual 
execution” whenever possible. In the elisa-based Capcellia 
technology, CD4 counting is automated. However, the 
Capcellia technology is expensive. Compared to the $ 3/test 
using the International Medical Center of Japan “Modified 
Dynabeads”,  [1]  the cost/test using the simple Capcellia 
technology is more than 5 times at $17/test. [3] Our 
hypothetical two levels modifications would reduce the 
cost/test of the “simple” Capcellia technology. The automated 
elisa plate reader counting of the CD4 cells makes the 
Capcellia technology compatible with our SMARThivPack 
model, thereby promoting “three tests” over “single test” in 
the clinical management of HIV patients, in resource-poor 
settings.  
 
Capcellia is an old technology developed in the 1990s. The 
world Health Organisation (WHO) previously declassified the 
older Capcellia technology as “obsolete”, and classified the 
newer Dynabeads technology in the pool of recommended 
technologies for the developing world. However, based on our 
standard favouring “automation” over, “human execution”, 
we determined that the old “simple” Capcellia technology is 
better suited than the new “complex” Dynabeads technology 
for monitoring HIV patients in resource-poor settings. 
Furthermore, the International Medical Center of Japan 
determined the Dynabeads technology “too complex” to 
justify its modification of the original Dynabeads protocol.  
 
SMARThivCD4mos is an intended component of the Biotech 
tropicana, Inc SMARThivPack. [3]  SMARThivPack is an 
intended component of the Biotech tropican, Inc “Life Box” 
comporting in addition to the SMARThivPack “three tests” 
Combo kit, an elisa plate reader and a PCR set up.  
 
The Biotech tropicana, Inc “Life Box” is an intended 
component of the Biotech tropicana, Inc 
SMARThivGLOBALmos, a third level global coordination 
cost and complexity reduction model comporting in addition 
to the SMARThivPack-based “Life Box”, alternative life 
boxes (“A-Life Box”) designed based on existing equipments 
in a specific laboratory to overcome cost and complexity.  
 
Overall, applying a cost reduction strategy developed at the 
International Medical Center of Japan, to reduce cost of the 
“complex” Dynabeads technology, we modelled a cost 
reduction strategy of the “simple” Capcellia technology, and 
design a new model technology that combines “simplicity” 
and “low cost” within a “single technology body”: 
SMARThivCD4mos. SMARThivCD4mos is compatible with 
our SMARThivPack model for improving HIV patients 
monitoring standards in resource-poor settings.  
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